Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Conference on Nuclear Medicine & Radiation Therapy Cologne, Germany.

Day 2 :

Keynote Forum

Pedro Serrano Ojeda

Caribbean Radiation Oncology Centre, USA

Keynote: The cancer solution: Cancer starvation therapy”-The end of cancer treatment failure

Time : 09:00-09:30

OMICS International Nuclear Medicine 2016 International Conference Keynote Speaker Pedro Serrano Ojeda photo

Dr. Pedro Serrano-Ojeda, M.D., a certified radiation oncologist, founded Caribbean Radiation Oncology Center in 2007 in Puerto Rico. He expanded the company a few years later with the announcement of its first facility outside of the island in Doral, Florida that opened in summer 2015. The facility is one of the first in Florida to feature the TomoTherapy HDA unit – the latest TomoTherapy Hi-Art Treatment System and the most integrated and advanced system for comprehensive cancer treatment that is available today.rnDr. Serrano-Ojeda received his medical degree from the Ponce School of Medicine & Health Sciences. In 2011, the American Association for Physics in Medicine publication named Caribbean Radiation Oncology Center as part of the guidelines for quality assurance for TomoTherapy technology, setting a new standard for care. Most recently the U.S. Patent and Trademark Office (PTO) has formally published his Cancer Starvation Therapy. Dr. Serrano-Ojeda is deeply committed to learning, to his patients and to his family. He lives in Coral Gables, Florida, with his wife and two daughters.rn


Adaptation and evolution are basic components of survival, a trait ubiquitous to all living species and unfortunately an ever present trait in cancer cells. The conference is a glimpse into the non-distant oncologic future about how we will overcome tumor treatment resistance through a medication; I have come to call Cancer Starvation Therapy (CST).rn

OMICS International Nuclear Medicine 2016 International Conference Keynote Speaker Marc Griffiths photo

Dr Marc Griffiths is an Associate Dean within the Faculty of Health and Applied Sciences at the University of the West of England, Bristol and completed his Professional Doctorate in 2014. His Professional Doctorate evaluated the impact of the introduction of new hybrid imaging technology on the nuclear medicine workforce. He has published a number of papers in peer reviewed journals related to the development of the nuclear medicine workforce and associated factors, including mentorship, education and training competencies. Marc works closely with education commissioners and is involved in healthcare workforce planning and scenario modelling.


Health professionals across the world now work within an environment of flux and uncertainty, which inevitably presents new opportunities and challenges for the workforce in terms of developing new skills and knowledge. The introduction of any new hybrid imaging technology may require appropriate staff training, considerations for service redesign and patient workflow dynamics, as part of the change process. Staffing a modern hybrid imaging environment requires a skilled and competent workforce, who should have the opportunity to further develop their working practice and clinical service provision. Balancing the needs of effective service delivery, workforce development and holistic patient-centric care requires careful planning and collaboration with a range of healthcare professionals. Introducing new hardware and software technology requires appropriate social frameworks, which may include ensuring clarity of role and responsibilities in order that the emerging relationship with the patient is maintained. There is a potential danger of ‘patient objectification’ during high technology examinations, such as hybrid imaging techniques, and the subsequent dehumanization process that may occur. Creating an environment where workforce flexibility is present, in terms of understanding the position of new technology within the patients’ journey and a greater understanding of the need to reshape the delivery of such clinical services, is paramount to the ongoing development of hybrid imaging within the modern healthcare domain.rn

Keynote Forum

Timo Joensuu

Docrates Cancer Center, Finland

Keynote: Multimodality approach in the treatment of metastatic prostate cancer

Time : 10:00-10:30

OMICS International Nuclear Medicine 2016 International Conference Keynote Speaker Timo Joensuu photo

Timo Joensuu is one of the leading European experts in prostate cancer with vast experience in both patient care and clinical studies. His special interests in the field of prostate cancer are multi-modality diagnostics, both internal and external radiotherapy and drug treatments. He can well be called as one of the Nordic pioneers in radiotherapy. He is one of the founders of Docrates Cancer Center, the only Nordic private cancer center providing all aspects of cancer diagnostics and treatments under one roof. The patient-centric care model is a driving force in his medical work, resulting among other things active participation on the patient organizations’ work both home and abroad.rn


Androgen deprivation has been the only treatment recommended by guidelines for metastatic prostate cancer. The radiotherapy and radiopharmaceuticals like Samarium are used mainly as pain killers. Hormonal therapies are well established but the problem is that castration resistant disease eventually emerges and then our patients are expected to survive about two years. Our personalized clinical practice has been to combine different treatment modalities in primarily metastatic prostate cancer in order to decrease the number of cancer cells as low as possible. Diagnostic procedures we start with ermp MRI of the prostate which will be done in most cases already before biopsies, followed by NaF-PET-CT and/or choline-/PSMA-PET-CT. First goal is to get PSA down (<1). All men receive mamillar irradiation with 12Gy, 6/9 Me-V. We combine LHRH analogs or Degarelix with bicalutamide plus zoledronic acid or denosumab and if it appears that we do not reach our first target we combine Docetaxel and most recently we have included also abiraterone/enzalutamide to the systemic therapy per need. Immediately, when our goal has been achieved we start radical VMAT radiotherapy of the prostate. We fuse all of our primary scanning with dose planning-CT and try to irradiate also bone metastases including also the lymph nodes to the target volumes. In addition some patients have received samarium intensified by mitoxantrone. The good feasibility of this multimodality approach and follow up-results will be presented.